The role of the innate immune system in ALS

Frontiers in Pharmacology

Volumn 3 AUG, Issue , 2012, Pages

  Phani, Sudarshan ^a,b   Re, Diane Berengere ^a,b   Przedborski, Serge ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Amyotrophic lateral sclerosis; Astrocyte; Innate immune system; Microglia; Motor neuron

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GLATIRAMER; MINOCYCLINE; PLACEBO;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTROCYTE; CELL FUNCTION; DRUG RESPONSE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MICROGLIA; MOTONEURON; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHARMACEUTICAL CARE; TREATMENT OUTCOME;

EID: 84866147136     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00150     Document Type: Article

References (51)

1. Andersen, P. M. (2001). Genetics of sporadic ALS. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2(Suppl. 1),S37-S41.
2. Angelov, D. N., Waibel, S., Guntinas-Lichius, O., Lenzen, M., Neiss, W. R, Tomov, T. L., Yoles, E., Kipnis, J., Schori, H., Reuter, A., Ludolph, A., and Schwartz, M. (2003). Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 100, 4790-4795.
3. Appel, S. H., Stewart, S. S., Appel, V., Harati, Y., Mietlowski, W., Weiss, W., and Belendiuk, G. W. (1988). A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch. Neurol. 45, 381-386.
4. Barbeito, A. G., Mesci, P., and Boillee, S. (2010). Motor neuron-immune interactions: the vicious circle of ALS. J. Neural Transm. 117, 981-1000.
5. Boillee, S., Vande Velde, C., and Cleveland, D. W. (2006a). ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52, 39-59.
6. Boillee, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kas-siotis, G., Kollias, G., and Cleveland, D. W. (2006b). Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389-1392.
7. Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Roth-stein, J. D., Borchelt, D. R., Price, D. L., and Cleveland, D. W. (1997). ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18, 327-338.
8. Chalmers, G. R., Peterson, D. A., and Gage, E H. (1996). Sprouting adult CNS cholinergic axons express NILE and associate with astrocytic surfaces expressing neural cell adhesion molecule. J. Comp. Neurol. 371, 287-299.
9. DeJesus-Hernandez, M., MacKenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adam-son, J., Kouri, N.,Wojtas, A., Sengdy, P., Hsiung, G. Y., Karydas, A., Seeley, W. W., Josephs, K. A., Coppola, G., Geschwind, D. H., Wszolek, Z. K., Feldman, H., Knopman, D. S., Petersen, R. C., Miller, B. L., Dickson, D. W., Boylan, K. B., Graff-Radford, N. R., and Rademakers, R. (2011). Expanded GGGGCC hexanu-cleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-256.
10. Dong, Y., and Benveniste, E. N. (2001). Immune function of astrocytes. Glia 36, 180-190.
11. Fischer, L. R., Culver, D. G., Ten-nant, P., Davis, A. A., Wang, M., Castellano-Sanchez, A., Khan, J., Polak, M. A., and Glass, J. D. (2004). Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185, 232-240.
12. Fray, A. E., Ince, P. G., Banner, S. J., Milton, I. D., Usher, P. A., Cook-son, M. R., and Shaw, P. J. (1998). The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study. Eur. J. Neurosci. 10,2481-2489.
13. Gong, Y. H., Parsadanian, A. S., Andreeva, A., Snider, W D., and Elliott, J. L. (2000). Restricted expression of G86R Cu/Zn superox-ide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 20, 660-665.
14. Gowing, G., Dequen, F., Soucy, G., and Julien, J. P. (2006). Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J. Neurosci. 26,11397-11402.
15. Hardiman, O., Van Den Berg, L. H., and Kiernan, M. C. (2011). Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7, 639-649.
16. Henkel, J. S., Beers, D. R., Zhao, W., and Appel, S. H. (2009). Microglia in ALS: the good, the bad, and the resting. J. Neuroimmune Pharmacol. 4, 389-398.
17. Hensley, K., Abdel-Moaty, H., Hunter, J., Mhatre, M., Mou, S., Nguyen, K., Potapova, T., Pye, Q. N., Qi, M., Rice, H., Stewart, C., Stroukoff, K., and West, M. (2006a). Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J. Neuroinflammation 3, 2.
18. Hensley, K., Mhatre, M., Mou, S., Pye, Q. N., Stewart, C., West, M., and Williamson, K. S. (2006b). On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid. Redox Signal. 8, 2075-2087.
19. Howland, D. S., Liu, J., She, Y., Goad, B., Maragakis, N. J., Kim, B., Erick-son, J., Kulik, J., Devito, L., Psaltis, G., Degennaro, L. J., Cleveland, D. W., and Rothstein, J. D. (2002). Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U.S.A. 99, 1604-1609.
20. Ince, P. G., Highley, J. R., Kirby, J., Whar-ton, S. B., Takahashi, H., Strong, M. J., and Shaw, P. J. (2011). Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol. 122, 657-671.
21. Jaarsma, D., Teuling, E., Haasdijk, E. D., De Zeeuw, C. I., and Hoogen-raad, C. C. (2008). Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J. Neurosci. 28, 2075-2088.
22. Karlsson, J., Fong, K. S., Hansson, M. J., Elmer, E., Csiszar, K., and Keep, M. F. (2004). Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosurg. 101,128-137.
23. Kawamata, T., Akiyama, H., Yamada, T., and McGeer, P. L. (1992). Immuno-logic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140, 691-707.
24. Kiaei, M., Petri, S., Kipiani, K., Gardian, G., Choi, D. K., Chen, J., Calingasan, N. Y., Schafer, P., Muller, G. W., Stewart, C., Hensley, K., and Beal, M. F. (2006). Thalidomide and lenalido-mide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 26, 2467-2473.
25. Kipnis, J., Avidan, H., Caspi, R. R., and Schwartz, M. (2004). Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia. Proc. Natl. Acad. Sci. U.S.A. 101(Suppl. 2), 14663-14669.
26. Kriz, J., Nguyen, M. D., and Julien, J. P. (2002). Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neuro-biol. Dis. 10,268-278.
27. Kwiatkowski, T. J. Jr., Bosco, D. A., Leclerc, A. L., Tamrazian, E., Van-derburg, C. R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E. J., Munsat, T., Valdmanis, P., Rouleau, G. A., Hosler, B. A., Cortelli, P., De Jong, P. J., Yoshinaga, Y., Haines, J. L., Pericak-Vance, M. A., Yan, J., Ticozzi, N., Siddique, T., McKenna-Yasek, D., Sapp, P. C., Horvitz, H. R., Landers, J. E., and Brown, Jr. R. H. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-1208.
28. Lepore, A. C., Rauck, B., Dejea, C., Pardo, A. C., Rao, M. S., Roth-stein, J. D., and Maragakis, N. J. (2008). Focal transplantation-based astrocyte replacement is neu-roprotective in a model of motor neuron disease. Nat. Neurosci. 11, 1294-1301.
29. MacKenzie, I. R., Bigio, E. H., Ince, P. G., Geser, F., Neumann, M., Cairns, N. J., Kwong, L. K., Forman, M. S., Ravits, J., Stewart, H., Eisen, A., McClusky, L., Kretzschmar, H. A., Monoranu, C. M., Highley, J. R., Kirby, J., Sid-dique, T., Shaw, P. J., Lee, V. M., and Trojanowski, J. Q. (2007). Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 61, 427-434.
30. Mantovani, S., Garbelli, S., Pasini, A., Alimonti, D., Perotti, C., Melazz-ini, M., Bendotti, C., and Mora, G. (2009). Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J. Neuroimmunol. 210, 73-79.
31. Maragakis, N. J., Dietrich, J., Wong, V., Xue, H., Mayer-Proschel, M., Rao, M. S., and Rothstein, J. D. (2004). Glutamate transporter expression and function in human glial progenitors. Glia 45, 133-143.
32. Meininger, V., Drory, V. E., Leigh, P. N., Ludolph, A., Robberecht, W., and Silani, V. (2009). Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler. 10, 378-383.
33. Moisse, K., and Strong, M. J. (2006). Innate immunity in amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762, 1083-1093.
34. Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., and Przedborski, S. (2007). Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 10, 615-622.
35. Napoli, I., and Neumann, H. (2009). Microglial clearance function in health and disease. Neuroscience 158, 1030-1038.
36. Okada, S., Nakamura, M., Katoh, H., Miyao, T., Shimazaki, T., Ishii, K., Yamane, J., Yoshimura, A., Iwamoto, Y., Toyama, Y., and Okano, H. (2006). Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat. Med. 12, 829-834.
37. Papadimitriou, D., Le Verche, V., Jacquier, A., Ikiz, B., Przedborski, S., and Re, D. B. (2010). Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol. Dis. 37, 493-502.
38. Pehar, M., Cassina, P., Vargas, M. R., Castellanos, R., Viera, L., Beckman, J. S., Estevez, A. G., and Barbeito, L. (2004). Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J. Neurochem. 89, 464-473.
39. Rothstein, J. D., Martin, L. J., and Kuncl, R. W. (1992). Decreased glu-tamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 326, 1464-1468.
40. Sanagi, T., Yuasa, S., Nakamura, Y., Suzuki, E., Aoki, M., Warita, H., Itoyama, Y., Uchino, S., Kohsaka, S., and Ohsawa, K. (2010). Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic trans-genic rat model of amyotrophic lateral sclerosis. J. Neurosci. Res. 88, 2736-2746.
41. Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., Baralle, F., De Belleroche, J., Mitchell, J. D., Leigh, P. N., Al-Chalabi, A., Miller, C. C., Nicholson, G., and Shaw, C. E. (2008). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319,1668-1672.
42. Sta, M., Sylva-Steenland, R. M., Casula, M., De Jong, J. M., Troost, D., Aron-ica, E., and Baas, F. (2011). Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol. Dis. 42,211-220.
43. Tan, C. F., Eguchi, H., Tagawa, A., Onodera, O., Iwasaki, T., Tsu-jino, A., Nishizawa, M., Kakita, A., and Takahashi, H. (2007). TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol. 113,535-542.
44. Turner, B. J., and Talbot, K. (2008). Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 85, 94-134.
45. Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P., Ganesalingam, J., Williams, K. L., Tripathi, V., Al-Saraj, S., Al-Chalabi, A., Leigh, P. N., Blair, I. P., Nicholson, G., De Belleroche, J., Gallo, J. M., Miller, C. C., and Shaw, C. E. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211.
46. Wang, L., Sharma, K., Grisotti, G., and Roos, R. P. (2009). The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis. Neurobiol. Dis. 35, 234-240.
47. Wijesekera, L. C., and Leigh, P. N. (2009). Amyotrophic lateral sclerosis. Orphanet. J. Rare Dis. 4, 3.
48. Wu, V W, Nishiyama, N., and Schwartz, J. P. (1998). A culture model of reactive astrocytes: increased nerve growth factor synthesis and reex-pression of cytokine responsiveness. J. Neurochem. 71, 749-756.
49. Yang, W W., Sidman, R. L., Taksir, T. V., Treleaven, C. M., Fidler, J. A., Cheng, S. H., Dodge, J. C., and Shihabuddin, L. S. (2011). Relationship between neuropathology and disease progression in the SOD1(G93A) ALS mouse. Exp. Neurol. 227, 287-295.
50. Yrjanheikki, J., Tikka, T., Keina-nen, R., Goldsteins, G., Chan, P. H., and Koistinaho, J. (1999). A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U.S.A. 96, 13496-13500.
51. Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., Gullans, S., Ferrante, R. J., Przedborski, S., Kristal, B. S., and Fried-lander, R. M. (2002). Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74-78.